Annual Review of Medicine 1991: Vol 42 Index

7 Pages·1991·1.1 MB·English

SUBJECT INDEX
A y and,
261-65
Acanthosis nigricans, 199, 202, linkage studies in, 152-54
373-78 log of odds (LOD) scores in,
treatment of, 378
ired immunodeficiency syn-
drome (AIDS), 69-82,
179-83, 221, 253-56, 287- AIDS-related complex (ARC)
93, 391-400, 403 AZT resistance and, 75
llergic i itial nephriti
Airway hyperresponsiveness,
and, 395 139-48
asthma and, 139-48
mechanisms for, 142-45
Alcohol withdrawal syndrome, ine abuse and, 133, 136-
323-37 37
assessment of, 325-26 Aspergillosis, 480-82
comorbidity, 325, 335-37 Asthma
complications of, 325, 33-35 airway hyperresponsiveness
and, 139-48
mechanism for, 142-45
Atheroma
stable, 37-38
ulcerated, 35
Atherosclerosis
lipoprotein transport gene
‘ ii abnormalities and, 357-
advanced glycosylation prod- 67
uct inhibition and, 159, Autoimmune disease, 459-67
and, 381, 385 164-65 Autoimmunity, 91-95, 189-95
immunophenotyping for, 381,
384, 387
retinoic acid and, 385-87
Acyclovir, 179, 181, 185, 248-
56
viral resistance to, 250-56
Adenine nucleotide pool
anaerobic glycosis and, 225—
26, 230-32
Adenosine triphosphate
regulation of cytosolic Ca”* Basal ganglia
and, 418-27 affective disorders and, 261-
: ic |
liver tumors and, 453-54 65
(ACTH) polycystic ovarian disease Battering
affective disorders and, 519- and, 199-204 child
30 Anemia see Child abuse
Advanced ylation end ic, 311-20 ign prostatic hypertrophy
products (AGEPs), 159-65 (BPH,1 0
irreversible accumulation of, accelerated, 36, 39-40
160-61 unstable, 4, 35-37, 40-44 treatment for alcohol with-
pathologic consequences of, stunned myocardium and, 4 drawal syndrome and,
161-64 Angioplasty 331-32, 336-37
Affective disorders, 151-57, hibernating myocardium and, Beta blockers
261-65, 519-30 1, 5-6 treatment for alcohol with-
drawal syndrome and,
Angioscopy, 35-36 331-32
Bipolar illness, 151-57
- .
Blood pressure
and, 214 diet and, 347-53
electrolytes and, 347-53
Bone cell metabolism, 17-23
585
nonexercise testing and, 122-
25
nuclear cardiology and, 119-
25
thallium scintigraphy and,
119-25
Coronary artery disease, 127-32
Coronary balloon dilation, 47-
56
physician’s legal responsibil- see Coronary angioplasty
ities and, 223 Coronary disease
Children
see Graft coronary disease
among, 403-8 Coronary thrombosis, 35-44
Chloride Corticosteroids
blood pressure and, 347-53 Pneumocystis carinii pneu-
Chronic myelogenous leukemia monitis and, 287
(CML), 169 Corticotropin-releasing hormone
Chronic pulmonary embolism, (CRH), 519-30
Bone modeling, 17-23 507-16 Cryoglobulinemia
mixed, 460
22 511-12 Cushing’s syndrome, 525
embolectomy and, 507-16 pseudo-, 528
Clindamycin, 287, 289 Cytogenetics
Cc Clonal origin, 167 acute myeloid leukemia and,
Clonality 381-84, 387
Cachexia i ic disor- Cytokines, 17-23, 25, 29, 567-
cancer, 205, 214 ders and, 491-502 79
Clonidi
Calcium bone cell metabolism and,
blood pressure and, 350-52 treatment for alcohol with- 17-23
drawal syndrome and, glomerular function and, 25,
29
wound repair and, 567-79
Cytomegalovirus, 61, 65-66,
179-85, 247-56, 303
myocardial stunning and, 3 transfusion-associated, 303
Calciuresis Schilling test for, 318-19 Cytomegalovirus (CMV) infec-
hypertension and, 350-51 Cocaine abuse tion, 179-85
Cancer arrhythmias and, 133, 136-37 prevention of, 183
multidrug resistance and treat- treatment of
ment of, 277-85 acyclovir and, 179, 181
prostate, 9--15 foscarnet and, 179, 182-
diagnosis of, 10-12 myocarditis and, 133, 135-36 83, 185
prostate-specific antigen spasm and, 133-35 ganciclovir and, 179, 181-
and, 9-15 Common acute lymphoblastic 82, 185
radical prostatectomy and, leukemia antigen (CALLA),
9 169 D
Staging of, 12-13 Congestive heart failure
treatment of, 13-15 diastolic dysfunction and, Dapasone, 292-93
see also Prostate cancer 411-32 Depression
Coronary angioplasty, 47-56 see Affective disorders
treatment for alcohol with- angiographic outcome of, 51
drawal syndrome and, clinical outcome of, 48-51
330 follow-up, 47 Diabetes mellitus, 159-65, 373-
Cardiomyopathy 75, 353-44
cocaine abuse and, 135-36 advanced glycosylation end
Cardiopulmonary bypass
myocardial stunning and, 4
Cell activation, 567, 568-79 Coronary artery disease, 119-25
Chemotaxis, 567, 569 Se 119, insulin-dependent, 373, 533
Chemotherapy non-insulin-dependent, 373-
exercisae i testing and, 75, 533
277-85 119-20 Diabetic hypertension, 533-44
SUBJECT INDEX 587
bone cell metabolism and,
17-23
Exercise stress testing, 119-22 glycosylation and, 159-65
Extracellular matrix wound repair and, 567-79
G :
glycosylation and, 159-65
ic hormone use and,
449, 452-53
H
HAIR-AN syndrome, 199, 201-
3
linkage analysis and, 202
Dideoxycytosine, 76-77 Hashimoto's thyroiditis
Dideoxyinosine, 77-78 autoimmune basis for, 91-95
Diet Hematologic disorders
hypertension and, 347-53 acquired, 491- 502
Differentiation, 381, 385-86
Foscarnet, 179, 182-83, 185,
acute myeloid leukemia cells
248, 251
and, 385-86
Difluoromethylomithine
(DFMO), 287, 289 G
Digital rectal examination, 10,
12 Gamma amino butyric acid
DNA (GABA)
advanced glycosylation end reguolf afootd iintaoken an d,
210
Ganciclovir, 179, 181-82, 185,
248, 251 Herpes simplex virus, 61-64,
viral resistance to, 251 247-57
Gene therapy, 277-85 types 1 and 2, 61-64
Genetics Herpesviruses, 61-66, 191,
lipoprotein transport proteins 247-57
and, 357-67 graft-versus-host disease and,
Genome, 61 191
Giardia lamblia, 406-7 herpes simplex virus, 61-64,
Glomerulonephritis, 25-31, 247-57
459-67 human, 61-66
cell-mediated immunity in, latency of, 61-66
25-31 number 6 (HHV6), 61, 66
human, 27-31
221 rapidly progressive, 27-28
pituitary- Glomerulosclerosis, 29-30, 391,
adrenocortical (HPA) 398-99
axis and, 519-30
Echocardiography, 119, 122
Elderly a mene 311, 316-20
organic depression in, 261-65 cobalamin deficiency and,
y and, 311, 316-20
Hormonal therapy, 9-10, 14-15
tuberculosis among, 267-75 Human herpes virus no. 6
(HHV6), 61, 66
Human immunodeficienvciryu s
ag 69-82, 301-2, 391-
Growth factors, 17-23, 159-65,
567-79
588 SUBJECT INDEX
interferon, 81-82 I
nonnucleoside reverse tran-
Immediate-early genes, 61-62
cell-mediated
glomerulonephritis and, 25-
31
Immunocompromised host, 287--
93
Immunoglobulin im-
— compounds,
Immunophenotyping
leukemia and, 381, 384, 387
Immunopropahxyi s
immunoglobulin, 179, 184-85
L
Immunosuppression
437, 440-42 Left ventricle
Immunotherapy, 179, 185 diastolic dysfunction and,
Infection 411-32
opportunistic diastolic pressure-volume rela-
cardiac tion and, 411
437, 440 Lethal perfusion injury, 225,
lymphocytotropic Infections 236-37
virus I related myelopathy, diarrheagenic, 403-8 Leukemia
97 AIDS and, 403 acute, 495, 499-500
, 199-204, children and, 403 acute myeloid, 381-87
373-78 mechanisms of. 403 ieti fac-
hyperinsulineamia and, 200-4 Inflammation tors and, 381, 385
treatment of, 377-78 lung function and, 139-48 immunophenotyping for,
platelet-dervived growth factor 384
and, 567-79 retinoic acid and, 385-87
Injury adult T-cell, 97-98, 100-1
heart bone marrow transplantation
irreversible, 225, 236-40 and, 189-95
reversible, 225, 236-40
Insulin-like growth factors
bone metabolism and, 20-21
Insulin receptor gene, 199-203
Hypertension, 347-53, 508, polycystic ovarian disease
514, 533-44 and, 199-203
calciuresis and, 350-51 Insulin receptors, 373, 376-77
diabetic, 533-44 Insulin resistance, 199-204,
sodium and, 537 373-717, 533, 538-41
diabetic nephropathy and, 535 polycystic ovarian disease affective disorders and, 151-
and, 199-204, 374 54
Hyperthyroidism acanthosis nigricans and, schizophrenia and, 155-56
373-78 i in
341-45 diabetes mellitus and, 373-75 high-density, 358, 363-65
Hypertrophy, 411, 417, 428-30, hyperandrogenism and, 373- low-density, 358-62
443-45 78 very-low-density, 358, 363-
Interferon, 81-82, 174-75 65
plasma cell myeloma and,
174-75 365-66
tumor progression and, 174- Lipoprotein lipase (LPL), 357-
75 58, 364-65
Loffler’s endocarditis, 418
mesenteric
acute, 107-17
nonocclusive, 107-17 disorders and, 151-56
SUBJECT INDEX 589
Low-density lipoprotein (LDL) Myelodysplasia, 491, 493, 498- Nursing homes, 267-75
heart disease risk 99 tubercle bacilli in, 267-75
and, 358-62 Myeloid metaplasia- tuberculosis among elderly in,
myelofibrosis, 495, 497 267-75
Myeloma Nutrition
multiple, 501 blood pressure and, 347-53
plasma cell, 167-75 Nutritional assessment, 549-63
Myeloproliferative disorders,
491, 495-99 oO
Myocardial infarction, 1-4, 35-
44, 133-35 Obesity, 205-14
cocaine abuse and, 133-35 autonomic nervous system
stunned myocardium and, | and, 211
thrombotic occlusion and, 42- genetic, 212-14
43 endocrine system and, 211-12
Myocardial ischemia, 1-6, 225- ventromedial hypothalamus
40 and, 212
Oncogenes, 167-75
chromosome abnormalities
jacrophages and, 169-70
glomerular dysfunction and, hibernating myocardium and, Osteo-induction factors, 22
25, 28-30 1, 5-6
glomerulosclerosis and, 29- reperfusion and, 226, 238-40 thyroid hormone and, 341-45
30 total, 228-35 Osteoporosis, 17, 341-45
proteinuria and, 28-29, 31 Myocardial relaxation, 411, thyroid hormone and, 341-45
ulcerated atheroma and, 35 418-32 Oxygen free radicals
Magnesium calcium and, 418-32 myocardial stunning and, 3, 5
blood pressure and, 347, Myocardial reperfusion, 1-5
351-52 stunned myocardium and, 1—5 P
Major depressive disorder, 151- Myocarditis
54 cocaine abuse and, 133, 135- Papaverine, 107, 110-17
linkage studies in, 152-54 36 nonocclusive mesenteric
Malnutrition, 549-63 Myocardium ischemia and, 107, 110-
Mania angioplasty and, 5—6 17
endocrinopathy and, 526 calcium homeostasis and, 3 Paranasal sinus infection, 471-
Manic-depressive disorder, 151- a ina bypass and, 88
57 immunocompromised hosts
Maltreatment cell death in, 2 and, 486-88
see Child abuse hibernating, 1-2, 5-6
Mechanical interdependence, coronary artery bypass sur- tropical spastic, 97-98, 101
139 gery and, 5 Parasitic diseases
Melphalan pharmacologic agents for, 5 transfusion-associated, 303-4
myeloma treatment and, 171- stunned, 1-5 Parathyroid hormone (PTH)
74 oxygen free radicals and, 3 bone metabolism and, 18,
Mesenteric ischemia, 107 unstable angina and, 4 20-23
acute, 107-17 Parathyroid hormone, 342
nonocclusive, 107-17 Pentamadine
N
papaverine and, 107, 110- aerosolized, 287, 289-91
17 intramuscular, 292
Metabolic bone disease, 17 Neoplasia intravenous, 292
Methylmalonate, 311, 316-20 clonal growth and, 491-502
cobalamin deficiency and, Nephropathy Percutaneous transluminal coro-
311, 316-20 HIV-associated, 391-400 nary angioplasty (PTCA)
Nephrotic syndrome
HIV virus and, 391-400 = eee
Nonadrenergic noncholinergic Pericardial constraint, 415-16
inhibitory (NANCT) system, Periventricular white matter
142 affective disorders and, 261—
airway hyperresponsiveness 64
P-glycoprotein, 277-80
hypertension and, 352
HTLV-I virus and, 102 Nuclear cardiology, 119-25 Pituitary adenomata, 525
590 SUBJECT INDEX
Plasrm a cell myelo' ma, 1l6i7ti- 75 Strength
hormones and,
and, 169-70 449, 451-55
treatment of, 171-75
Platelet-derived growth factor, myocardial ischemia and, 1—
5, 225
— lupus erythematosus,
dialysis and, 131 Systemic vasculitis, 459-67
factors influencing incidence
of, 130-31
T
intimal hyperplasia and, 127-
32
pathophysiologic mechanisms Tat inhibitors, 80
of, 128-30 Thallium scintigraphy, 119-
prevention of, 131-30 25
Restriction fragment length Thrombolysis, 1, 3-4
Thrombocythemia, 495, 498
Thrombosis
Polycythemia vera, 491, 497-98 pulmonary artery, 515
Polymyositis, 97 venous, 508
Potassium Thrombus
blood pressure and, 347, leukemia treatment with, 385— restenosis and, 128-29
349-50, 352 87 Thyroid peroxidase, 91-95
Prednisone Retroviral infections Thyroid-stimulating hormone,
myeloma treatment and, 171- non-AIDS, 97-103 92-93
74 Thyrotropin (TSH), 341-45
Primaquine, 287 Thyrotopin-releasing hormone,
S
Prostate cancer, 9-5 342-43
diagnosis of, 10-12 Transcription, 61, 63
Salmonella, 406 Transforming growth factor beta
Schilling test for cobalamin family (TGFB)
ion, 318-19 bone metabolism and, 21-
Schizophrenia, 151-57, 526- 22
27 Transfusion
endocrinology and, 526-27 AIDS and, 297
genetic epidemiology of, 154—- audit criteria for, 297-300
Protein-sparing, 549, 554-55 55 autologous, 297, 300-1,
glomerular macrophages and, linkage studies in, 155-56 307
28-29 log of odds (LOD) scores” disease risk from, 301-4
glomerulosclerosis and, 29 and, 155-56 homologous, 297, 301
Protooncogenes, 381, 386-87 Sepsis, 549-52 minimal exposure, 301
acute myeloid leukemia and, Skeletal tissue, 17-23 viral inactivation for blood
386-87 Sinusitis components and, 297,
docrinology, 520 paranasal, 471-88 306
immunocompromised hosts Transplantation
and, 486-88 bone marrow, 189-95
Small inducible genes, 571- cardiac, 437-46
74 rejection and, 439, 443
Sodium Transrectal ultrasonography, 9,
hypertension and, 347-53 11-12
Radical prostatectomy, 9, 13-15 Spasm Trimethoprim-dapsone, 287-88,
Radionuclide angiography, 423 cocaine abuse and, 133-35 292-93
Reactivation, 61-62 Splanchnic vasoconstriction, Trimethoprim-sulfamethoxazole,
Recombifftht CD4, 78-79 107-17 288-93
Renal disease Starvation, 550 Trimetrexate, 287-88
end-stage, 391, 393-400 Sterility Tropical spastic paraplegia, 97-
Renal disease anabolic hormones and, 449, 98, 101-2
cell-mediated immunity in, 452 Tubercle bacilli, 267-75
25-31 Steroids Tuberculin skin test, 267-75
See also Glomerulonephritis, see Androgens, Corticoster- Tumor progression, 167-75
Glomerulosclerosis oids interferon and, 174-75
SUBJECT INDEX 591
Vv Vexamil, 277-78, 282-85 Working Group on Hypertension
Very-low-density lipoprotein in Diabetes, 543-44
Valproic acid coronary heart disease risk Wound repair, 567-79
treatment for alcohol with- and,
drawal syndrome and, Victims Z
331 child abuse, 217-24
Varicella-Zoster virus, 61, 64, see also Child abuse
247, 249-S6 Vinblastine, 277-80 Zidovudine (AZT), 69-76, 82,
Vasculitis Vincristine
systemic, 459-67 myeloma treatment and, 173
Vasoactive intestinal peptide
(VIP) WwW
airway hyperresponsiveness
and, 142
Vasopressin Wegener’s granulomatosis, 459,
affective disorders and, 524—- 460
25 Wegener's vasculitis, 459-67